Jhunjhunwala's holding reduces in this key Tata subsidiary; IKS now at the top of the portfolio

While date as per Ace Equities shows that the Jhunjhunwalas had invested Rs 17,481 crore at the end of the September quarter, the holding has come down to Rs 14,741 crore now.

Titan, the company that kept the Jhunjhunwala's interested in almost two decades is now seeing major trims in their portfolio. Inventurus Knowledge Solutions (IKS) is now at the top of their portfolio, replacing Titan for the first time, at a holding value of Rs 16,319.

IKS is a new entrant in the Jhunjhunwala portfolio, that was listed on the National Stock Exchange (NSE) in December 2024. Its price band was at Rs 1,329 and current value is at Rs 1651. It hit record high of Rs 2,190 on 26 Dec 24 while its lowest was on January 28, at Rs 1,559.

Rekha Jhunjhunwala's, wife of veteran investor, late Rakesh Jhunjhunwala, holdings in Titan have reduced in terms of value by about 15 percent amid market corrections, as calculated from the September quarter to the December quarter of FY 2025.

While data as per Ace Equities shows that the Jhunjhunwalas had invested Rs 17,481 crore at the end of the September quarter, the holding has come down to Rs 14,871 crore at the end of its December quarter. Total Jhunjhunwala family stake stands at 5.14 percent (4,57,13,470 shares) stake in the Tata group's subsidiary (as of December 31).

On the other hand, the date of the two quarter's holdings also reveals a subtle increase in value of holdings across Fortis Healthcare, Indian Hotel and Star Health & Allied Insurance. No major changes were observed in any of the other large holdings such as Metro Brands, Tata Motors and NCC Ltd.

Titan is trading close to its 52-week low, and this major drop in the Jhunjhunwala's holdings indicates a major reallocation. The shares of the company have undergone major corrections of about 15 percent, from over Rs 3,800 as the peak value.

The Jhunjhunwala's had started investing in the stock as early as 2002, with the adjusted prices of trading being close to Rs 4. As of 2024, the company shares fell about 11.5 percent.

34 analysts are currently covering the stock, with 17 iterating a 'buy' while 12 have rated it as 'hold' and five call for a 'sell'.

IKS Health (IKS) is a Platform as a Service (PaaS) company that caters to US’ healthcare provider segment. It focusses on outsourcing the routine chores of physicians. ICICI Securities in its latest note called IKS among its top pick due to a superior financial performance, technology prowess and attractive large-scale opportunity. Thus, recommending 'Hold' with a target price of Rs 1,820 (based on 35x FY2027 Earnings Per Share)